FindTrial
Sign In

Profile changes following a treatment involving devices to loosen the sutures of the upper jaw( by expanding and contracting alternately) and to pull the upper jaw forward.

Soft tissue and dentoskeletal profile changes associated with a combined protocol of Alternate Maxillary Expansion-Constriction and Reverse Headgear therapy with and without Class III elastics -A Randomized Controlled Trial - AltRAMEC-C3E

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2013/09/004027
Enrollment
36
Registered
2013-09-27
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients with Skeletal Class III malocclusion due to maxillary deficiency

Interventions

Intervention1: Altramec with Reverse Headgear with Class III elastics: Effect of adding elastics during the alternate expansion constriction and facemask will be studied Control Intervention1: Altrame

Sponsors

Dr Puthen Purackel Jean James
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 7-12 years (CVMI stage less than or equal to CS3) Skeletal class III with maxillary retrusion as evidenced by ANB less than 0 and/or negative or zero overjet Class III molar relationship

Exclusion criteria

Exclusion criteria: Craniofacial abnormalities Congenitally missing teeth CVMI Stage- CS3 and above Previous orthodontic or orthopaedic treatment.

Design outcomes

Primary

MeasureTime frame
Dentoskeletal and Soft tissue profile changesTimepoint: 6 months before treatment, just before treatment, after treatment—

Secondary

MeasureTime frame
No secondary outcomesTimepoint: not applicable—

Countries

India

Contacts

Public ContactDr Puthen Purackel Jean James

Government Dental College Kozhikode

drshobhakumar@gmail.com919447067245

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026